Cathy Kelly

6 days ago | insights.citeline.com | Cathy Kelly

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program. Ruling is first of several expected from the Third Circuit on the negotiation program. (Shutterstock)

1 week ago | insights.citeline.com | Cathy Kelly

Most Favored Nation Pricing Policy Floated In Medicaid, Coming Back To Medicare? President Trump's ongoing interest in the policy, which would ensure the US government pays no more for prescription drugs than the lowest price available in comparable countries, continues to gain attention. The Most Favored Nation policy has not been considered in Medicaid before. (Shutterstock)

2 weeks ago | insights.citeline.com | Cathy Kelly

Raising Drug Prices In The EU Could Take Years, Even If Pharma Effort Succeeds Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US. After years of trying, can pharma get higher prices in the EU? (Shutterstock)

2 weeks ago | insights.citeline.com | Cathy Kelly

PBMs No Longer Profit From Rebates But Plans Benefit; Should Sponsors Push More For Reform? Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients. Current PBM reform legislation is missing the mark. (Shutterstock)

2 weeks ago | insights.citeline.com | Cathy Kelly

340B Not Designed To Pass Savings Directly To Patients, Hospitals Tell Senate Committee Respondents to a Senate investigation that could re-energize 340B reform efforts said hospitals offer patient assistance programs and use 340B revenue for “capital improvement projects” and “community benefit programs,” though they do not account for specific program revenue allocations. A key Senate committee endorses 340B legislative reforms. (Shutterstock)